Currently conducted at the Lille University Hospital, DIVE is a revolutionary clinical
trial on Parkinson's disease. It is based on the development and evaluation of a new
system for administering the treatment of the disease by infusing the missing
dopamine directly into the brain in order to limit the side effects of conventional
treatments. An original manufacturing process is thus being produced for the first time
at the Lille University Hospital. This new technology was developed by InBrain
Pharma, a start-up created to exploit the initial concept resulting from academic
research at the Lille University Hospital, the University of Lille and the Lille
Neuroscience & Cognition UMR-S 1172 Inserm laboratory. The technology transfer
was carried out by SATT Nord with incubation at Eurasanté. More information...